Assessment of Serum Soluble CD30 Levels in Pediatric Kidney Transplant Recipients
Publicado en línea: 03 ene 2024
Páginas: 102 - 108
Recibido: 14 ago 2023
Aceptado: 10 nov 2023
DOI: https://doi.org/10.3889/seejim.2023.6057
Palabras clave
© 2023 Alaa A. Rashad et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
BACKGROUND
CD30 is considered to be a marker for the activated immune system; however, its association with acute rejection and kidney graft function showed severe heterogeneity.
AIM
The aim of this study is to examine the predictive value of soluble CD30 (sCD30) levels for kidney transplantation (KT) outcomes in children.
MATERIALS AND METHODS
CD30 in serum was measured by ELISA technique in 50 pediatric kidney transplant recipients (KTRs) within 13.4 ± 4.5 days before and within 19.5 ± 9.2 days after KT. sCD30 values were correlated with clinical, laboratory, and immunosuppressive (IS) therapy data and graft function of included patients. Twenty age/gender-matched healthy controls participated as reference values for sCD30 levels.
RESULTS
Our study revealed that serum levels of CD30 showed a significant relation between serum sCD30 levels: Pre/post-transplantation (p = 0.02) with increasing sCD30 levels after transplantation (71.60 pg/mL vs. 90.20 pg/mL). In the time, there were no relations between sCD30 with other parameters.
CONCLUSIONS
Our results suggest that the measurement of serums CD30 levels may be used as a valuable biomarker in renal transplantation when it is measured pre/post-transplantation.